The technology allows to reduce costs and time for drug development, providing a high level of success and reliable patent protection.

[3] In 2014, SOM Biotech initiated a phase IIa proof of concept study in humans, regarding its compound SOM0226 for treatment of TTR Amyloidosis, with Vall d´Hebron Hospital in Barcelona.

From 2018 to 2019, SOM Biotech successfully performed a clinical proof-of-concept phase IIa study assessing SOM3355 efficacy and safety in reducing chorea in Huntington’s disease.

In 2013, SOM Biotech was the winner of the Entrepreneur XXI Award in biotechnology in the category "Growth", an initiative for innovation projects promoted by La Caixa together with the Spanish Ministry of Industry, Energy and Tourism, and ENISA.

[12] In 2020 and 2021 SOM Biotech was included in the list of the Spanish startups and scaleups to watch in, published by Sifted, a Financial Times backed company.